Experience

Paladin Labs

• Canada
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• National Sales Manager

  • Apr 2023 - Present

• Regional Key Account Manager

  • Jul 2020 - Present

  Un poste a double role, être responsable d'une équipe de gestionnaires de comptes majeurs en plus d'être responsable de gérer les comptes assigné. Dans trois champs thérapeutiques , Troubles du mouvement, Transplantation rénale et hépatique ainsi que l'oncologie.


open to new oppotunities in pharmaceutical and biotechnology industry
• Key Accounts Manager, orphan drugs and rare diseases

  • 2019 - Jul 2020


Bioverativ

• United States

• Key Accounts Manager, Hemophilia

  • 2015 - 2018

  Promotion or Alprolix and Eloctate Recombinant Factor FIX and Factor VIII for patient with Haemophilia B and Haemophilia A, given by infusion. Promotion among Haematologists, nurses and Haemophilia treatment centers staff members. Collaboration with Marketing, Medical, Regulatory, Reimbursement. • Manages and executes local and international learning activities to drive diagnosis and treatment rates, in collaboration with the medical affairs for physician and other healthcare… Show more Promotion or Alprolix and Eloctate Recombinant Factor FIX and Factor VIII for patient with Haemophilia B and Haemophilia A, given by infusion. Promotion among Haematologists, nurses and Haemophilia treatment centers staff members. Collaboration with Marketing, Medical, Regulatory, Reimbursement. • Manages and executes local and international learning activities to drive diagnosis and treatment rates, in collaboration with the medical affairs for physician and other healthcare professionals. • Launch Year in the Eastern Territory, finishing HI at 438% to target for Alprolix and 170% for Eloctate. H2 targets were adjusted upwards significantly and I rose to the challenge, achieving 133.8% to Target for Alprolix and 136,9 % for Eloctate in H2. Show less Promotion or Alprolix and Eloctate Recombinant Factor FIX and Factor VIII for patient with Haemophilia B and Haemophilia A, given by infusion. Promotion among Haematologists, nurses and Haemophilia treatment centers staff members. Collaboration with Marketing, Medical, Regulatory, Reimbursement. • Manages and executes local and international learning activities to drive diagnosis and treatment rates, in collaboration with the medical affairs for physician and other healthcare… Show more Promotion or Alprolix and Eloctate Recombinant Factor FIX and Factor VIII for patient with Haemophilia B and Haemophilia A, given by infusion. Promotion among Haematologists, nurses and Haemophilia treatment centers staff members. Collaboration with Marketing, Medical, Regulatory, Reimbursement. • Manages and executes local and international learning activities to drive diagnosis and treatment rates, in collaboration with the medical affairs for physician and other healthcare professionals. • Launch Year in the Eastern Territory, finishing HI at 438% to target for Alprolix and 170% for Eloctate. H2 targets were adjusted upwards significantly and I rose to the challenge, achieving 133.8% to Target for Alprolix and 136,9 % for Eloctate in H2. Show less



Biogen

• South Africa
• Wellness and Fitness Services
• 1 - 100 Employee

• Key Accounts Manager, Neurology

  • 2010 - 2014

  Promotion of Tysabri Natalizumab a monoclonal antibody for the treatment of Multiple Sclerosis given by infusion. Promotion among Neurologists, nurses and MS society. Collaboration with staff members, Marketing, Medical, Regulatory affairs and reimbursement. • Despite a very competitive environment, reached and exceeded or the territory’s objectives year after year (Sales Quota, Market Share and reach and frequency and maintained market share every year. • 2nd position in Canada for… Show more Promotion of Tysabri Natalizumab a monoclonal antibody for the treatment of Multiple Sclerosis given by infusion. Promotion among Neurologists, nurses and MS society. Collaboration with staff members, Marketing, Medical, Regulatory affairs and reimbursement. • Despite a very competitive environment, reached and exceeded or the territory’s objectives year after year (Sales Quota, Market Share and reach and frequency and maintained market share every year. • 2nd position in Canada for Tysabri sales in 2013. • Best sales performance in Canada with more than 110% vs 2012 sales objectives. • 2nd position in Canada for Tysabri sales in 2011. • 3rd position in Canada for Tysabri sales in 2010.

• Area Business Manager, Neurology

  • 2008 - 2010

  Promotion of Avonex Interferon Beta-1a and Tysabri Natalizumab a monoclonal antibody for the treatment of Multiple Sclerosis given by infusion. Promotion among Neurologists, nurses and MS society staff members. • Despite a very competitive environment, exceeded territory’s objectives the first year (sales quota, market share). • Liaison between costumer and company for two external patient management programs (Inomar)



Abbott

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Pharmaceutical Representative

  • 2008 - 2008

  Focus on GP’s and Specialists, including Cardiologists (Mavik, Meridia, Syntroid) Focus on GP’s and Specialists, including Cardiologists (Mavik, Meridia, Syntroid)



LIPSO SYSTEMS INC.

• Key Account Director

  • 2006 - 2007

  Responsible for business development in Quebec. Reached sales objective of 2M$ and maintained leadership in the mobile solutions market. • New market development: Opened markets in new business segments pharmaceutical sector (ie. Pfizer) and banking sector (ie. Moneris Solution). • Managing existing clients: Contract renewal and on-going development of new projects with existing key accounts (Astral media, Société Radio Canada, Réseau Canoë, Bell, Rogers Media… Show more Responsible for business development in Quebec. Reached sales objective of 2M$ and maintained leadership in the mobile solutions market. • New market development: Opened markets in new business segments pharmaceutical sector (ie. Pfizer) and banking sector (ie. Moneris Solution). • Managing existing clients: Contract renewal and on-going development of new projects with existing key accounts (Astral media, Société Radio Canada, Réseau Canoë, Bell, Rogers Media, Cossette). • Implementation of client solutions: Interface between Lipso’s technical team, the clients’ needs, and the mobility operators (CWTA). Show less Responsible for business development in Quebec. Reached sales objective of 2M$ and maintained leadership in the mobile solutions market. • New market development: Opened markets in new business segments pharmaceutical sector (ie. Pfizer) and banking sector (ie. Moneris Solution). • Managing existing clients: Contract renewal and on-going development of new projects with existing key accounts (Astral media, Société Radio Canada, Réseau Canoë, Bell, Rogers Media… Show more Responsible for business development in Quebec. Reached sales objective of 2M$ and maintained leadership in the mobile solutions market. • New market development: Opened markets in new business segments pharmaceutical sector (ie. Pfizer) and banking sector (ie. Moneris Solution). • Managing existing clients: Contract renewal and on-going development of new projects with existing key accounts (Astral media, Société Radio Canada, Réseau Canoë, Bell, Rogers Media, Cossette). • Implementation of client solutions: Interface between Lipso’s technical team, the clients’ needs, and the mobility operators (CWTA). Show less



Pfizer

• Events Services
• 1 - 100 Employee

• Hospital Representative

  • 2002 - 2006

  Representative in urology and neurology (Viagra Relpax, Detrol) • Despite a very competitive environment, reached and exceeded or the territory’s objectives year after year (sales quota, market share and reach and frequency and maintained market share every year. • Best individual sales performance for Quebec and among the best three for Canada (Circle of Excellence 2002). • Best team sales performance for Canada during two consecutive years (District of the Year 2003 and… Show more Representative in urology and neurology (Viagra Relpax, Detrol) • Despite a very competitive environment, reached and exceeded or the territory’s objectives year after year (sales quota, market share and reach and frequency and maintained market share every year. • Best individual sales performance for Quebec and among the best three for Canada (Circle of Excellence 2002). • Best team sales performance for Canada during two consecutive years (District of the Year 2003 and 2004). • Development of a strong network of contacts giving Pfizer a high profile presence in many strategic projects. • Launch of projects in new therapeutic fields in order to promote Pfizer’s products (prostate cancer and cardiovascular problems). • Gained access to residents by developing programs in urology and neurology. • Recruitment and training of doctors for participation in conferences.

• District Manager – Medical communication

  • 1999 - 2002

  Responsible for medical communication in all therapeutic fields for Quebec. (Cardiology, Mental Health, Rheumatology, Erectile, dysfunction) • Adaptation of Canadian training programs to Quebec’s specific needs and management of accreditation process. • Created and developed medical communication division for Quebec. • Liaised with Canadian Head Office for development of training programs for all brands. • Finalised partnerships with key actors: regional medical associations… Show more Responsible for medical communication in all therapeutic fields for Quebec. (Cardiology, Mental Health, Rheumatology, Erectile, dysfunction) • Adaptation of Canadian training programs to Quebec’s specific needs and management of accreditation process. • Created and developed medical communication division for Quebec. • Liaised with Canadian Head Office for development of training programs for all brands. • Finalised partnerships with key actors: regional medical associations, University Medical Communication services, doctor’s groups, etc. • Controlled over district team’s observance of Rx & D codes, criteria, norms and the credit attribution modes. • 6 to 7 training programs launched every year in different therapeutic areas versus 2 to 3 programs per prior years.

• Pharmaceutical Representative

  • 1997 - 1999

  • Promotion of four products among general practitioners and specialists in clinics, hospitals and pharmacies. • Market development for mental disorders (treatment of Alzheimer - Aricept).



Eli Lilly and Company

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Pharmaceutical Representative

  • 1992 - 1999

  • Launch of Prozac and market development for mental health sector. • Maintained market share despite new competitive entrants onto market. • Participated in the development of promotional material for Prozac. • Launch of Prozac and market development for mental health sector. • Maintained market share despite new competitive entrants onto market. • Participated in the development of promotional material for Prozac.